A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin

Peer Review reports

Original Submission
15 Apr 2017	Submitted	Original manuscript
23 Apr 2017	Reviewed	Reviewer Report - Yoshifumi Saisho
4 May 2017	Reviewed	Reviewer Report - Akinobu Nakamura
12 Jun 2017	Author responded	Author comments - Seung-Hwan Lee
Resubmission - Version 2
12 Jun 2017	Submitted	Manuscript version 2
17 Jun 2017	Reviewed	Reviewer Report - Yoshifumi Saisho
21 Jun 2017	Reviewed	Reviewer Report - Akinobu Nakamura
12 Jul 2017	Author responded	Author comments - Seung-Hwan Lee
Resubmission - Version 3
12 Jul 2017	Submitted	Manuscript version 3
22 Sep 2017	Author responded	Author comments - Seung-Hwan Lee
Resubmission - Version 4
22 Sep 2017	Submitted	Manuscript version 4
Publishing
13 Oct 2017	Editorially accepted
6 Nov 2017	Article published	10.1186/s12902-017-0219-x

Back to article page